Back
Open Access

What do we know now that could have changed the history of CETP Inhibition? Genetics and biology

Session: Innovating the clinical management of LDL-c: exploring CETP as therapeutic target
Topic: Pharmacology and Pharmacotherapy
Speaker: Professor J. Kastelein (Amsterdam, NL)
Sponsored by PACE-CME - Supported by an unrestricted educational grant from NewAmsterdam Pharma & Menarini
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Professor John Kastelein

Antoni van Leeuwenhoek Hospital (AVL), Amsterdam (Netherlands (The))
36 presentations
6 followers

4 more presentations in this session

Introduction

Speaker: Professor K. Ray (London, GB)

Access
Slides
Video
Like
Thumbnail

CETP inhibition: lessons from two decades of clinical trials

Speaker: Professor S. Nicholls (Melbourne, AU)

Access
Slides
Video
Like
Thumbnail

A novel CETP-inhibitor to target CV risk reduction: where could it fit in future lipid management?

Speaker: Professor E. Michos (Baltimore, US)

Access
Slides
Video
Like
Thumbnail

Discussion

Speaker: Professor K. Ray (London, GB) Professor G. Norata (Milan, IT)

Access
Video
Like
Thumbnail

Access the full session

Innovating the clinical management of LDL-c: exploring CETP as therapeutic target

Speakers: Professor J. Kastelein, Professor K. Ray, Professor S. Nicholls, Professor E. Michos, Professor K. Ray...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources